(12) United States Patent
`Dugi et al.
`
`(10) Patent N0.:
`(45) Date of Patent:
`
`US 9,173,859 B2
`*Nov. 3, 2015
`
`US009l73859B2
`
`(54) USES OF DPP IV INHIBITORS
`
`(71) Applicants:Klaus Dugi, Dresden (DE); Frank
`Himmelsbach, Mittelbiberach (DE);
`Michael Mark, Biberach an der Riss
`(DE)
`
`(72)
`
`Inventors: Klaus Dugi, Dresden (DE); Frank
`Himmelsbach, Mittelbiberach (DE);
`Michael Mark, Biberach an der Riss
`(DE)
`
`(73) Assignee: Boehringer Ingelheim International
`GmbH, Ingelheim am Rhein (DE)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`This patent is subject to a terminal dis-
`claimer.
`
`(21) Appl.No.: 14/161,007
`
`(22)
`
`Filed:
`
`Jan. 22, 2014
`
`(65)
`
`Prior Publication Data
`
`US 2014/0135348 A1
`
`May 15,2014
`
`Related U.S. Application Data
`
`(63) Continuation of application No. 12/946,193, filed on
`Nov. 15, 2010, now Pat. No. 8,673,927, which is a
`continuation of application No. 11/744,703, filed on
`May 4, 2007, now Pat. No. 8,232,281.
`
`(30)
`
`Foreign Application Priority Data
`
`May 4,2006
`
`(EP) ................................... .. 06009203
`
`(51)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. Cl.
`A61K 31/52
`A61K 31/155
`A61K 31/197
`A61K 31/4985
`A61K 31/522
`(52) U.S. Cl.
`CPC ........... .. A61K31/155 (2013.01); A61K31/197
`(2013.01); A61K 31/4985 (2013.01); A61K
`31/522(2013.01);Y10S 514/866 (2013.01)
`(58) Field of Classification Search
`CPC
`A61K 31/52; A61K 31/155; A61K 31/197
`USPC ................................... .. 514/263.21, 635, 868
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2,056,046 A
`2,375,138 A
`2,629,736 A
`2,730,544 A
`2,750,387 A
`2,928,833 A
`3,174,901 A
`
`9/1936 Fourneau
`5/1945 Salvin
`2/1953 Krimmel
`1/1956 Sahyun
`6/1956 Krimmel
`3/1960 Leake et al.
`3/1965 Sterne
`
`3,236,891 A
`3,454,635 A
`3,673,241 A
`3,925,357 A
`4,005,208 A
`4,061,753 A
`4,382,091 A
`4,599,338 A
`4,639,436 A
`4,687,777 A
`4,743,450 A
`4,816,455 A
`4,873,330 A
`4,968,672 A
`5,041,448 A
`5,051,517 A
`5,084,460 A
`5,130,244 A
`5,164,526 A
`5,219,870 A
`5,223,499 A
`5,234,897 A
`5,258,380 A
`5,266,555 A
`5,273,995 A
`5,284,967 A
`5,300,298 A
`5,329,025 A
`5,332,744 A
`
`2/1966 Seemuller
`7/1969 Muth
`6/1972 Marxer
`12/1975 Okada et al.
`1/1977 Bender et al.
`12/1977 Bodor et al.
`5/1983 Benjamin et al.
`7/1986 Regnier et al.
`1/1987 Junge et al.
`8/1987 Meguro et al.
`5/1988 Harris et al.
`3/1989 Schickaneder et al.
`10/1989 Lindholm
`11/1990 Jacobson et al.
`8/1991 Janssens et al.
`9/1991 Findeisen et al.
`1/1992 Munson, Jr. et al.
`7/1992 Nishimaki et al.
`11/1992 Macher
`6/1993 Kim
`6/1993 Greenlee et al.
`8/1993 Findeisen et al.
`11/1993 Janssens et al.
`ll/1993 Findeisen et al.
`12/1993 Roth
`2/1994 Macher
`4/1994 LaNoue
`7/1994 Wong et al.
`7/1994 Chakravarty et al.
`
`(Continued)
`
`FOREIGN PATENT DOCUMENTS
`
`AU
`AU
`
`2003280680 Al
`2009224546 Al
`
`6/2004
`9/2009
`
`(Continued)
`OTHER PUBLICATIONS
`
`Kroller-Schon, S. et al., “Glucose-independent Improvement ofVas-
`cular Dysfunction in Experimental Sepsis by Dipeptidyl Peptidase-4
`Inhibition” Cardiovascular Research, 2012, vol. 96, No. 1, pp. 140-
`149.
`Lakatos, P. L. et a1., “Elevated Serum Dipeptidyl IV (CD26, EC
`3.4.14.5) Activity in Experimental Liver Cirrhosis.” European Jour-
`nal of Clinical Investigation, 2000, vol. 30, No. 9, pp. 793-797.
`Lambier, A.M. et al., Dipeptidyl-Peptidase IV from Bench to Bed-
`side: An Update on Structural Properties, Functions, and Clinical
`Aspects of the Enzyme DPP IV. Critical Reviews in Clinical Labo-
`ratory Sciences, 2003, 40(3), p. 209-294.
`Lee Jones, K. et al., “Effect of Metformin in Pediatric Patients With
`Type 2 Diabetes.” Diabetes Care, 2002, vol. 25, No. 1, pp. 89-94.
`(Continued)
`
`Primary Examiner — Kevin E Weddington
`(74) Attorney, Agent, orFirm — Michael P. Morris; David L.
`Kershner
`
`(57)
`
`ABSTRACT
`
`The specification describes the use of selected DPP IV inhibi-
`tors for the treatment of physiological functional disorders
`and for reducing the risk of the occurrence of such functional
`disorders in at-risk patient groups. In addition, the use of the
`above-mentioned DPP IV inhibitors in conjunction with
`other active substances is described, by means of which
`improved treatment outcomes can be achieved. These appli-
`cations may be used to prepare corresponding medicaments.
`
`22 Claims, No Drawings
`
`MYLAN Ex. 1001, Page 1
`
`MYLAN Ex. 1001, Page 1
`
`

`
`US 9,173,859 B2
`Page 2
`
`(56)
`
`References Cited
`
`US. PATENT DOCUMENTS
`
`5,389,542 A
`5399578 A
`5,407,929 A
`5,451,055 A
`5,470,579 A
`5,591,752 A
`5,594,003 A
`5,502,127 A
`5,514,519 A
`5,719,279 A
`5,728,849 A
`5,753,535 A
`5,830,908 A
`5,879,708 A
`5,958,951 A
`5,955,555 A
`5,955,592 A
`5,011,049 A
`5,107,302 A
`5,155,053 A
`5,248,758 B1
`5,303,551 B1
`5,342,501 B1
`5,372,940 B1
`5,548,481 B1
`5,579,858 B1
`5,727,251 B2
`5,784,195 B2
`6,821,978 B2
`5,859,947 B2
`5,995,183 B2
`7,050,722 B2
`7,074,794 B2
`7,074,798 B2
`7,074,923 B2
`7,109,192 B2
`7,179,809 B2
`7,183,280 B2
`7,192,952 B2
`7,217,711 B2
`7,235,538 B2
`7,247,478 B2
`7,291,642 B2
`7,351,587 B2
`7,393,847 B2
`7,407,955 B2
`7,407,995 B2
`7,432,252 B2
`7,439,370 B2
`7,470,715 B2
`7,475,571 B2
`7,482,337 B2
`7,495,002 B2
`7,495,003 B2
`7,495,005 B2
`7,501,426 B2
`7,550,455 B2
`7,550,450 B2
`7,555,707 B2
`7,559,574 B2
`7,579,449 B2
`7,510,153 B2
`7,545,753 B2
`7,718,555 B2
`7,754,481 B2
`7,799,732 B2
`7,820,815 132
`7,838,529 B2
`8,039,477 B2
`8,071,583 B2
`8,106,060 B2
`8,119,648 B2 *
`8,158,633 B2
`8,178,541 B2 *
`8,232,281 B2
`
`2/1995 13515511 5131.
`3/1995 Bu1111113y51 5131.
`4/1995 T3k3h3Sh15131.
`10/1995 G5115k5 5131.
`11/1995 B01115 5131.
`1/1997 H311515131.
`1/1997 H31151 5131.
`2/1997 H31151 5131.
`3/1997 H311515131.
`2/1998 Kufn51_Muh1 5131.
`3/1998 B5115113111 5131.
`5/1998 Bu5k111311 5131.
`11/1998 G1-u11511b51g 5131.
`3/1999 1\/13111115 5131.
`9/1999 A111111115131.
`10/1999 51515511 5131.
`10/1999 Bu1111113y51 5131.
`1/2000 W1111551111,
`8/2000 C31151 5131.
`12/2000 V1111131151
`5/2001 K151111515 5131.
`10/2001 13511111111 5131.
`1/2002 B311115k 5131.
`4/2002 C3V3ZZ3
`4/2003 13511111111 5131.
`5/2003 AS3110 5131.
`4/2004 Gobbi 5131.
`8/2004 H315 5131.
`11/2004 Chackalamarmil et al.
`3/2005 K311511111) 5131.
`2/2005 H311131111 5131.
`5/2005 K113111113 5131.
`7/2005 K113j1m3 5131.
`7/2006 Yoshikawa et al.
`7/2005 13311311111131 5131.
`9/2005 H311515131.
`2/2007 13511113111151 31.
`2/2007 H111111151Sb3511 5131.
`3/2007 K311511111) 5131.
`5/2007 13511113151151 31.
`5/2007 K311511111) 5131.
`7/2007 1313511131111 51 31.
`11/2007 Kauffmarm-Hefner et al.
`4/2008 B31111 5131.
`7/2008 13511113111151 31.
`8/2008 H1mm51Sb35h 5131.
`8/2008 Qk 5131.
`10/2008 13511113111151 31.
`10/2008 135111131111
`12/2008 13511113151151 31.
`1/2009 13511113111151 31.
`1/2009 H111111151Sb3511 5131.
`2/2009 L311gk0pf5131.
`2/2009 13511113111151 31.
`2/2009 Himmelsbach et a1.
`3/2009 Himmelsbach et a1.
`5/2009 H111111151Sb3511 5131.
`7/2009 13511113111151 31.
`7/2009 13511113111151 31.
`8/2009 M3151 5131.
`8/2009 13511113111151 31.
`10/2009 C31151, Jr. 5131.
`1/2010 H1mm51Sb35h 5131.
`5/2010 B55111111g51 5131.
`7/2010 1313511131111 51 31.
`9/2010 Munson 5131.
`10/2010 Pfrengle e131,
`11/2010 Himmelsbach et al.
`10/2011 Hendrix et a1.
`12/2011 Himmelsbach
`1/2012 Pfrengle et al.
`2/2012 Himmelsbach et a1.
`4/2012 Hendrix et al.
`5/2012 Himmelsbach et a1.
`7/2012 Dugi et a1.
`
`. 514/263.21
`
`. 514/263.21
`
`8,673,927 B2 *
`8,679,520 B2
`8,785,455 B2
`8,865,729 B2
`8,962,636 B2
`2001/0020006 A1
`2001/0051646 A1
`2002/0019411 A1
`2002/0137903 A1
`2002/0161001 A1
`2002/0169174 A1
`2002/0198205 A1
`2003/0078269 A1
`2003/0100563 A1
`2003/0105077 A1
`2003/0114390 A1
`2003/0130313 A1
`2003/0149071 A1
`2003/0166578 A1
`2003/0199528 A1
`2003/0224043 A1
`2003/0232987 A1
`2003/0236272 A1
`2004/0023981 A1
`2004/0034014 A1
`2004/0037883 A1
`2004/0063725 A1
`2004/0077645 A1
`2004/0082570 A1
`2004/0087587 A1
`2004/0097510 A1
`2004/0116328 A1
`2004/0122048 A1
`2004/0122228 A1
`2004/0126358 A1
`2004/0138214 A1
`2004/0138215 A1
`2004/0152720 A1
`2004/0166125 A1
`2004/0171836 A1
`2004/0180925 A1
`2004/0259903 A1
`2005/0020574 A1
`2005/0026921 A1
`2005/0032804 A1
`2005/0065145 A1
`2005/0070552 A1
`2005/0070594 A1
`2005/0130985 A1
`2005/0143377 A1
`2005/0171093 A1
`2005/0187227 A1
`2005/0203095 A1
`2005/0234108 A1
`2005/0234235 A1
`2005/0239778 A1
`2005/0244502 A1
`2005/0256310 A1
`2005/0261271 A1
`2005/0251352 A1
`2005/0266080 A1
`2005/0276794 A1
`2006/0004074 A1
`2006/0034922 A1
`2006/0039974 A1
`2006/0047125 A1
`2006/0058323 A1
`2006/0063787 A1
`2006/0074058 A1
`2006/0079541 A1
`2006/0094722 A1
`2006/0100199 A1
`2006/0106035 A1
`2006/0111372 A1
`2006/0111379 A1
`2006/0134206 A1
`2006/0142310 A1
`2006/0154866 A1
`2006/0159746 A1
`
`............. .. 514/263.21
`
`3/2014 Dugi et al.
`3/2014 Horres et al.
`7/2014 Hotter et 211.
`10/2014 Sieger et al.
`2/2015 Pfrengle et al.
`9/2001 Demuth et al.
`12/2001 Demuth et al.
`2/2002 Robl et al.
`9/2002 Ellsworth et al.
`10/2002 Kanstrup et 211.
`11/2002 Chackalamannil et al.
`12/2002 Himmelsbach et al.
`4/2003 Pearson et al.
`5/2003 Edmondson et 211.
`6/2003 Kanstrup et :11.
`6/2003 Washburn et al.
`7/2003 Fu11n0eta1.
`8/2003 G0bb1 et al.
`9/2003 Arch et al.
`10/2003 Kanstrup et 211.
`12/2003 Appel et al.
`12/2003 Dahanukar et :11.
`12/2003 Carr
`2/2004 Ren et al.
`2/2004 Kanstrup et :11.
`2/2004 Zhou et al.
`4/2004 Barth et al.
`4/2004 Himmelsbach et al.
`4/2004 Yoshikawa et al.
`5/2004 Himmelsbach et al.
`5/2004 Himmelsbach et al.
`6/2004 Yoshikawa et al.
`6/2004 Beryamln et a1.
`6/2004 Maier et al.
`7/2004 Warne et al.
`7/2004 Himmelsbach et al.
`7/2004 Eckhardt et 211.
`8/2004 Hartig et 81.
`8/2004 Himmelsbach et al.
`9/2004 Fujino et al.
`9/2004 Matsuno et al.
`12/2004 Boehringer et al.
`1/2005 Hauel et al.
`2/2005 Eckhardt et 211.
`2/2005 Cypes et al.
`3/2005 Cao et al.
`3/2005 Jones et a1~
`3/2005 Kauschke et al.
`6/2005 Himmelsbach et al.
`6/2005 Himmelsbach et al.
`8/2005 Eckhardt et al.
`8/2005 Himmelsbach et al.
`9/2005 Eckhardt et al.
`10/2005 Himmelsbach et al.
`10/2005 Eckhardt et :11.
`10/2005 Konetzki et al.
`11/2005 Mathias et al.
`11/2005 Hulin et al.
`11/2005 Feng et a1.
`11/2005 Eckhélrdt
`12/2005 Desai et al.
`12/2005 Papas et :11.
`1/2006 Eckhardt et :11.
`2/2006 Cheng et al.
`2/2006 Akiyama et :11.
`3/2006 Leonardi et :11.
`3/2006 Eckh_ardt et 211.
`3/2006 Yoshikawa et al.
`4/2006 Holmes et al.
`4/2006 Langkopf et :11.
`5/2006 Yasuda et al.
`5/2006 Yoshikawa et al.
`5/2006 Hendrix et 211.
`5/2006 Hendrix et 211.
`5/2006 Guillemont et al.
`6/2006 Iyer et al.
`6/2006 Pfrengle et al.
`7/2006 Chu et al.
`7/2006 Troup et a1.
`
`MYLAN Ex. 1001, Page 2
`
`MYLAN Ex. 1001, Page 2
`
`

`
`(56)
`
`References Cited
`
`Us. PATENT DOCUMENTS
`
`2006/0173056 A1
`2006/0205711 A1
`2006/0205943 A1
`2006/0247226 A1
`2006/0270668 A1
`2005/0270701 A1
`2007/0027153 A1
`2007/0060530 A1
`2007/0072803 A1
`2007/0072810 A1
`
`2007/0088038 A1
`2007/0093659 A1
`2007/0142383 A1
`2007/0185091 A1
`2007/0196472 A1
`
`8/2006 Kitajimaetal.
`9/2006 H1mme1SbaChe1a11
`9/2006 Daha1111ka1e1811
`11/2006 Himmelsbach etal.
`11/2006 CheWe1a11
`11/2005 K10111 017111
`2/2007 pf1eng1e 53131.
`3/2007 Christopher et al.
`3/2007 Chu et al.
`3/2007 Asakawa
`
`4/2007 Eckhard_teta1.
`4/2007 Bonfantlet al.
`6/2007 Eckhardt et al.
`8/2007 Himmelsbach etal.
`8/2007 Kiel et al.
`
`2007/0259900 A1
`
`11/2007 Siegeretal.
`
`2007/0281940 A1
`2007/0299076 A1
`
`12/2007 Dugietal.
`12/2007 Piotrowski etal.
`
`2008/0108816 A1
`
`5/2008 Zutter
`
`2008/0312243 A1
`
`12/2008 Eckhardtetal.
`
`2009/0088408 A1
`2009/0088569 A1
`
`4/2009 Meade etal.
`4/2009 Eckhardtetal.
`
`2009/0136596 A1
`
`5/2009 Munson etal.
`
`2009/0186086 A1
`
`7/2009 Shankaretal.
`
`2009/0301105 A1
`2009/0325926 A1
`
`12/2009 Loelting
`12/2009 Himmelsbach
`
`2010/0092551 A1
`
`4/2010 Nakamuraetal.
`
`2010/0183531 A1
`2010/0204250 A1
`
`7/2010 Johncocketal.
`8/2010 Himmelsbach etal.
`
`2010/0310664 A1
`2011/0009391 A1
`
`12/2010 Watson etal.
`1/2011 Braunetal.
`
`2011/0092510 A1
`
`4/2011 Kleinetal.
`
`2011/0144083 A1
`2011/0144095 A1
`
`6/2011 Himmelsbach etal.
`6/2011 Himmelsbach etal.
`
`2011/0195917 A1
`2011/0206766 A1
`
`8/2011 Dugietal.
`8/2011 Friedl etal.
`
`2011/0275561 A1
`
`11/2011 Graefe-Modyetal.
`
`2012/0035158 A1
`2012/0040982 A1
`2012/0053173 A1
`2012/0094894 A1
`2012/0107398 A1
`2012/0121530 A1
`2012/0122776 A1
`2012/0129874 A1
`
`2/2012 H1mme1sbacheta1.
`2/2012 H1mme1sbach et :11.
`3/2012 Banno etal.
`4/2012 Graefe-Modyet al.
`5/2012 Schneideret al.
`5/2012 Klein etal.
`5/2012 Graefe-Mody et al.
`5/2012 Sieger et al.
`
`US 9,173,859 B2
`Page 3
`
`2012/0142712 A1
`2012/0165251 A1
`2012/0208831 A1
`2012/0219622 A1
`
`2012/0219623 A1
`2012/0252782 A1
`2012/0252783 A1
`2012/0296091 A1
`2013/0122089 A1
`2013/0172244 A1
`2013/0184204 A1
`2013/0196898 A1
`2013/0236543 A1
`
`6/2012 Pfrengle et al.
`6/2012 Klein etal.
`8/2012 Himmelsbach et al.
`8/2012 Kohlrausch et al.
`
`8/2012 Melnlcke
`10/2012 H1mme1sbacheta1.
`10/2012 H_1mme1sbacheta1.
`11/2012 Slegeretal.
`5/2013 K0111rausch et al.
`7/2013 K1e1n etal.
`7/2013 Pfrengle et al.
`8/2013 Dugiet al.
`9/2013 Ito et a1.
`
`FOREIGN PATENT DOCUMENTS
`
`E:
`CA
`
`CA
`
`CA
`CA
`
`CA
`
`CA
`
`CA
`CA
`
`DE
`
`DE
`
`DE
`DE
`
`E1,
`
`E1,
`E1,
`
`E1,
`E1,
`
`E1,
`
`E1,
`E1,
`
`E1,
`E1,
`
`E1,
`
`E1,
`E1,
`E1.
`EP
`Ep
`Ep
`EP
`EP
`
`:1
`2418656 A1
`
`Z139?
`272002
`
`2496325 A1
`
`372004
`
`2508233 A1
`2529729 A1
`
`672004
`12/2004
`
`2556064 A1
`
`972005
`
`2562859 A1
`
`11/2005
`
`2651019 A1
`2651089 A1
`
`11/2007
`11/2007
`
`2758025 A1
`
`771979
`
`10238243 A1
`
`372004
`
`102004044221 A1
`102004054054 A1
`
`372006
`572006
`
`0223403 A2
`
`571987
`
`0342675 A2
`0389282 A2
`
`0400974 A2
`409281 A1
`
`11/1989
`971990
`
`12/1990
`171991
`
`0475482 A1
`
`371992
`
`0775704 A1
`0950658 A1
`
`571997
`10/1999
`
`1066265 A1
`1310245 A1
`
`172001
`572003
`
`1406873 A2
`
`472004
`
`1535906 A1
`1537880 A1
`1557165 A1
`1586571 A1
`1743555 A1
`1750076
`1829877 A1
`1852108 A1
`
`672005
`6/2005
`7/2005
`10/2005
`1/2007
`3/2007
`9/2007
`11/2007
`
`MYLAN Ex. 1001, Page 3
`
`MYLAN Ex. 1001, Page 3
`
`

`
`(56)
`
`References Cited
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`Es
`Es
`Es
`FR
`GB
`HU
`HU
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`KR
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`1397392 A2
`2143443 A1
`335302 A1
`2255797 T3
`2253057 T3
`2707541 A1
`2034530 A
`9003243
`9902303 A2
`$374395 A
`770120
`3333339
`11193270
`2000502534 A
`2001213770 A
`2001273312 A
`2002348279 A
`2003286287 A
`2003300977 A
`2004151749 A
`2004250335 A
`2005045155 A
`2010053575 A
`2010070575 A
`2010524530 A
`20070111099 A
`9107945 A1
`9205175 A1
`9219227 A2
`9402150 A1
`9403455 A1
`9532173 A1
`9509045 A1
`9511917 A1
`9535533 A1
`9723447 A1
`9723473 A1
`9745525 A1
`9307725
`9311393
`9313770 A1
`9322454 A1
`9323007 A1
`9340059 A2
`9345032 A1
`9355405 A1
`9929595 A1
`9933501 A2
`9950243 A1
`9955551 A1
`9957279 A1
`0073307 A2
`0107441 A1
`0140130 A2
`0151919
`0152325
`0152325 A2
`0152352 A1
`0155543 A1
`0153545 A1
`0172290 A2
`0177110 A1
`0195301 A1
`0197303 A1
`0202550 A2
`0214271 A1
`0224698 A1
`0253516 A2
`02068420 A1
`03000241 A2
`03002531 A2
`03004496 A1
`03024965 A2
`03033686 A2
`03034944 A1
`
`3/2003
`1/2010
`4/1973
`7/2005
`12/2005
`1/1995
`4/1932
`5/1990
`7/2000
`5/1952
`3/1995
`12/1995
`7/1999
`3/2000
`3/2001
`10/2001
`12/2002
`10/2003
`10/2003
`5/2004
`9/2004
`2/2005
`3/2010
`4/2010
`7/2010
`11/2007
`5/1991
`4/1992
`11/1992
`2/1994
`2/1994
`11/1995
`3/1995
`4/1995
`11/1995
`7/1997
`7/1997
`12/1997
`2/1993
`3/1993
`5/1993
`5/1993
`7/1993
`9/1993
`10/1993
`12/1993
`5/1999
`3/1999
`10/1999
`11/1999
`12/1999
`12/2000
`2/2001
`5/2001
`7/2001
`7/2001
`7/2001
`7/2001
`9/2001
`9/2001
`10/2001
`10/2001
`12/2001
`12/2001
`1/2002
`2/2002
`3/2002
`7/2002
`9/2002
`1/2003
`1/2003
`1/2003
`3/2003
`4/2003
`5/2003
`
`US 9,173,859 B2
`Page 4
`
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`03037327 A1
`03053929 A1
`03055881 A1
`03057200 A2
`03064454 A1
`03088900 A2
`03094909 A2
`03099279 A1
`03099836 A1
`03103629 A1
`03104229 A1
`03106428 A1
`2004002924 A1
`2004011416 A1
`2004016587 A1
`2004018467 A2
`2004018468 A2
`2004018469 A1
`2004028524 A1
`2004033455 A1
`2004035575 A1
`2004041820 A1
`2004046148 A1
`2004048379 A1
`2004050658 A1
`2004052362 A1
`2004058233 A1
`2004062689 A1
`2004065380 A1
`2004074246 A2
`2004081006 A1
`2004082402 A1
`2004096806 A1
`2004096811 A1
`2004106279 A2
`2004108730 A1
`2004111051 A1
`2005000846 A1
`2005000848 A1
`2005007647 A1
`2005007658 A2
`2005012288 A1
`2005023179 A2
`2005049022 A2
`2005051950 A1
`2005058901 A1
`2005061489 A1
`2005063750 A1
`2005082906 A1
`2005085246 A1
`2005092870 A1
`2005092877 A1
`2005095343 A1
`2005095381 A1
`2005097798 A
`2005116000 A1
`2005116014 A1
`2005117861 A1
`2005117948 A1
`2006005613 A1
`2006027204 A1
`2006029577 A1
`2006029769 A1
`2006036664 A1
`2006040625 A1
`2006041976 A1
`2006047248 A1
`2006048209 A1
`2006048427 A1
`2006068163 A1
`2006071078 A1
`2006076231 A2
`2006083491 A2
`2006135693 A2
`2006137085 A1
`2007007173 A2
`2007014886 A1
`2007014895 A2
`2007017423 A1
`
`5/2003
`7/2003
`7/2003
`7/2003
`8/2003
`10/2003
`11/2003
`12/2003
`12/2003
`12/2003
`12/2003
`12/2003
`1/2004
`2/2004
`2/2004
`3/2004
`3/2004
`3/2004
`4/2004
`4/2004
`4/2004
`5/2004
`6/2004
`6/2004
`6/2004
`6/2004
`7/2004
`7/2004
`8/2004
`9/2004
`9/2004
`9/2004
`11/2004
`11/2004
`12/2004
`12/2004
`12/2004
`1/2005
`1/2005
`1/2005
`1/2005
`2/2005
`3/2005
`6/2005
`6/2005
`6/2005
`7/2005
`7/2005
`9/2005
`9/2005
`10/2005
`10/2005
`10/2005
`10/2005
`10/2005
`12/2005
`12/2005
`12/2005
`12/2005
`1/2006
`3/2006
`3/2006
`3/2006
`4/2006
`4/2006
`4/2006
`5/2006
`5/2006
`5/2006
`6/2006
`7/2006
`7/2006
`8/2006
`12/2006
`12/2006
`1/2007
`2/2007
`2/2007
`2/2007
`
`MYLAN Ex. 1001, Page 4
`
`MYLAN Ex. 1001, Page 4
`
`

`
`US 9,173,859 B2
`Page 5
`
`(56)
`
`References Cited
`
`WO
`WO
`
`2013098372 A1
`2013103629 A1
`
`7/2013
`7/2013
`
`FOREIGN PATENT DOCUMENTS
`2007033350 A1
`3/2007
`2007035355 A2
`3/2007
`2007035555 A1
`3/2007
`2007041053 A2
`4/2007
`2007071738
`6/2007
`
`1
`
`OTHER PUBLICATIONS
`_
`Levien,T.L. et al, “New drugs in development for the treatment of
`diabetes”, Diabetes Spectrum, American Diabetes Association, US,
`vol. 22, No. 2, Jan. 1, 2009, pp. 92-106.
`Lovshin, J.A. et al., “Incretin-based therapies for type 2 diabetes
`melli111s.
`I:Ia11ure RGZIGWS Er11doc11inol1ogy,12009, vol. 5, pp. 2162269.
`\/Iarc , J. Awvance Organic C emistry. Reactions, Mec anisms,
`and Structure . Fourth Edition, 1992, pp. 652-653.
`\/Iatsumiya, Teruhiko, et al., “Therapeutic Drugs for Clinicians”
`Diagnosis and Treatment (2008) vol. 96, No. 2 pp. 389-390.
`\/Iayo Clinic Staff: “Nonalchoholic fatty liver disease: Prevention”
`-
`-
`-
`-
`-
`[retrieved on Nov. 30, 2012]. retrieved from the Internet:
`,URL:
`http.//www.mayoclinic.com/health/nonalcoholic-fatty-liver-dis-
`ease/DS00577DSECTION:prevent1on>.
`1
`\/Iedline Plus, “Obesity” 2013, Retrieved from internet on Aug. 22,
`2013, http://www.nlm.nih.gov/medlineplus/obesity.htrnl.
`\/Ieece, J. “When Oral Agents Fail: Optimizing Insulin Therapy in the
`Older Adult”. Consultant Pharmacist, The Society, Arlington, VA
`US. vol. 24, No. Suppl B, Jun. 1, 2009, p. 11-17.
`\/Iendes F D et al “Recent advances in the treatment of non-alco-
`.
`’
`'
`.
`’
`.
`'
`,,
`.
`.
`.
`.
`holic fatty liver disease . Expert Opinion on Investigational Drugs,
`vol. 14, No. 1, Jan. 1, 2005,1129-35.
`\/Ierck: “Initial Therapy with Janumet (sitagliptin/metforrnin) pro-
`vided significantly greater blood sugar
`lowering compared to
`metforrnin alone in patients with type 2 diabetes”. Webwire.com,
`,
`-
`-
`Junr.) 8,4 2009, p.
`1-4. http.//www.webwire.corn/ViewPressRel.
`“P: ‘*1d’95595~ “
`_
`_
`_
`\Iathan, D. et al., Management of Hyperglycemia in Type 2 Diabe-
`tes: A Consensus Algorithm for the Initiation and Adjustment of
`Therapy.” Diabetes Care, Aug. 2006, vol. 29, No. 8, pp. 1963-1972.
`\Iauck, M. A. et al., “Efficacy and Safety ofAdding the Dipeptidyl
`Peptidase-4 Inhibitor Alogliptin to Metformin Therapy in Patients
`with Type 2 Diabetes Inadequately Controlled with Metformin
`\/Ionotherapy: A Multicentre, Randomised, Double-Blind, Placebo-
`(\Z1otro11le(1v1Stu1(41y. Elir11ica111§’14r111ctice, 201(1)8,Sv(f)l. 63,1\I(1)1.1 1,
`46-1515.1
`3“? ’
`'
`2°.
`3 " .
`. °?‘°y an
`3 ety. °
`6
`‘Pew Y
`Pept1d_ase-4 Inhibitor, Sitagliptin, Compared with the Sulfonylurea,
`Glipizide, in Patients with Type 2 Diabetes Inaduately Controlled on
`\/Ietformin alone: A Randomized, Double-Blind, Non-Inferiority
`Trial.” Diabetes Obesity and Metabolism, 2007, vol. 9, No. 2, pp.
`194-205.
`\Iielsen, L., “Incretin Mimetics and DPP-IV Inhibitors for the Treat-
`ment ofType 2 Diabetes.” DDT, 2005, vol. 10, No. 10, pp. 703-710.
`\Iielsen, L., “Incretin mimetics and DPP-IV inhibitors for the treat-
`r1r1)en1:pof7t1y3pe720diabetes. Drug Discovery Today, 2005, vol. 10, No.
`\Iihon Ijinpo, Japan Medicinal Journal, 2001, No. 4032, p. 137.
`O’Farre1l, et al., “Pharmacok1netic and Pharmacodynamic Assess-
`ments of the Dipeptidyl Pept1dase-4 Inhibitor PHX1149: Double-
`Blind, Placebo-controlled, Single-and Multiple-Dose Studies in
`Healthy Subjects”. Clinical Therapeutics, Excerpta Medica,
`Princeton, NJ, vol. 29, No. 8, 2007, p. 1692-1705.
`Oflice Action for U.S.App1.No. 10/695,597 mailed May 2, 2008.
`Patani George A. et al.: “Bioisoterism : A Rational Approach in Drug
`Design”, Chemical Reviews, 1996, vol. 96, No. 8, pp. 3147-3176.
`Pei, Z.: “From the bench to the bedside: Dipeptidyl peptidase IV
`i(r)1h_ib_itors, a new class of oral antihyperglycernic agents Current
`pinion in Drug Discovery and Development, Current Drugs, Lon-
`don, GB vol. 11,No. 4:1Jul. 1, 2008 pp. 5112-5321
`1
`1
`1
`Plummer, C.J.G. et al., The Effect ofMelting Point Distributions on
`DSC Melting Peaks.” Polymer Bulletin, 1996, vol. 36, pp. 355-360.
`Pospisilik, et a1; Dipeptidyl Peptidase IV Inhibitor Treatment Stimu-
`lates ? —Cell Survival and Islet Neogenesis in Streptozotocin-In-
`duced Diabetic Rats; Diabetes, vol. 52, Mar. 2003 pp. 741-750.
`Pratley, R. et al., “Inhibition of DPP-4: a new therapeutic approach
`for the treatment of type 2 diabetes.” Current Medical Research and
`Opinion, 2007, vol. 23, No.4, pp. 919-931.
`
`MYLAN Ex. 1001, Page 5
`
`872007
`9/2007
`10/2007
`10/2007
`11/2007
`11/2007
`11 2007
`1172007
`11/3007
`12/2007
`12/2007
`12/2007
`1/2008
`1/2008
`2/2008
`2/2008
`5/2008
`5/2008
`6/2008
`7/2008
`7/2008
`772008
`8 2008
`873008
`9/2008
`10/2008
`10/2008
`11/2008
`1/2009
`2/2009
`2/2009
`
`373009
`5/2009
`8/2009
`9/2009
`9/2009
`10/2009
`10/2009
`12/2009
`2/2010
`
`472010
`
`7/2010
`8/2010
`3/2010
`8/2010
`8/2010
`8/2010
`9/2010
`12/2010
`
`4/3011
`6/2011
`9/2011
`11/2011
`11/2011
`12/2011
`12/2011
`3/2012
`5/2012
`8/2012
`9/2012
`
`2007093610 41
`2007099345 A1
`2007120702 A2
`2007120935 A2
`2007128721 A
`2007128724 A1
`2007135196 A2
`2007128701 A2
`3007137107 43
`2007147185 A1
`2007143135 A2
`2007149797 A2
`2008005569 A2
`2008005576 A1
`2008017570
`2008022267 A2
`2008055870 A1
`2008055940 A2
`2008070692 A2
`2008081205 A1
`2008083238 A2
`2008087198 A1
`2008093878 A1
`3008093883 41
`2008113000 A1
`2008130998 A2
`2008131149 A2
`2008137435 A1
`2009011451 A
`2009022007 A1
`2009022008 A1
`
`3009034543 43
`2009063072 A2
`2009099734 A1
`20091 1 1200 A1
`20091 12591 A2
`2009121945 A2
`2009123992 A1
`2009147125 A1
`2010015664 A1
`
`2010043688 41
`
`WO
`W0
`W0
`WO
`WO
`$8
`WO
`WO
`WO
`W0
`WO
`W0
`WO
`W0
`WO
`WO
`W0
`W0
`WO
`W0
`W0
`W0
`WO
`WO
`W0
`WO
`W0
`W0
`WO
`WO
`W0
`W0
`WO
`WO
`WO
`W0
`W0
`$8
`WO
`W0
`W0
`W0
`W0
`W0
`WO
`WO
`W0
`$8
`WO
`$8
`2010079197 A1
`WO
`2010086411 A1
`WO
`2010092124 A1
`W0
`2010092125 A1
`W0
`2010092163 A2
`WO
`2010096384 A2
`WO
`2010105457 A2
`W0
`2010147758 A1
`W0
`$8 3;
`WO
`3011039367 43
`WO
`2011064352 A1
`WO
`2011113947 A1
`W0
`2011138380 A1
`W0
`2011133421 A1
`W0
`2011 151 151 A1
`W0
`2011153205 A2
`W0
`2012031124 A2
`WO
`2012065993 A1
`WO
`2012106303 A1
`WO
`2012120040 A1
`
`MYLAN Ex. 1001, Page 5
`
`

`
`US 9,173,859 B2
`Page 6
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Priimenko, B. A., et al; Synthesis and Pharmacological Activity of
`Derivates of 6,8-Dimethyl
`Imidazo(1,2-f) Xanthine-(Russ.);
`Khimiko-Farmatsevticheskii zhurnal (1984) vol. 18, No. 12 pp.
`1456-1461.
`Rhee eta1.: “Nitrogen-15-Labeled Deoxynucleosides. 3. Synthesis of
`[3-15N]-2'-Deoxyadenosine” J. Am. Chem. Soc. 1990, 112, 8174-
`8175.
`Rosenbloom, et al., “Type 2 Diabetes mellitus in the child and ado-
`lescent”, Pediatric Diabetes, 2008, p. 512-526.
`Rosenstock, et al., “Efficacy and tolerability of initial combination
`therapy with vildagliptin and pioglitazone compared with component
`montherapy in patients with type 2 diabetes”. Diabetes, Obesity and
`Metabolism, Mar. 2007, vol. 9, No. 2, p. 175-185.
`Rosenstock, et al., Sitagliptin Study 019 Groups, Efficacy and safety
`ofthe dipeptidyl peptidase-4 inhibitor sitagliptin, Clinical Therapeu-
`tics, 2006, vol. 28, Issue 10, p. 1556-1568.
`Rosenstock, J. et al., “Alogliptin added to insulin therapy in patients
`with type 2 diabetes reduces HbA1c without causing weight gain or
`increased hypoglycaemia”. Diabetes, Obesity and Metabolishm,
`Dec. 2009, vol. 11. No. 12, p. 1145-1152.
`Russell-Jones, D. et al., “Liraglutide vs insulin glargine and placebo
`in combination with metformin and sulfonylurea therapy in type 2
`diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial”
`Diabetologia, 2009, vol. 52, pp. 2046-2055.
`Salomon, J., et al; Ultraviolet and g-Ray-Induced Reactions of
`Nucleic Acid Constituents. Reactions of Purines with Amines; Pho-
`tochemistry and Photobiology (1974) vol. 19 pp. 21-27.
`Sarafidis, P. et al., “Cardiometabolic Syndrome and Chronic Kidney
`Disease: What is the link?”JCMS 2006, 1: p. 58-65.
`Sathananthan, A., et al., “Personalized pharmacotherapy for type 2
`diabetes mellitus”. Personalized Medicine 2009 Future Medicine
`Ltd, vol. 6, No. 4, Jul. 2009, p. 417-422.
`Sauer, R, et al. “Water-soluble phosphate prodrugs of 1-Propargyl-
`7-styrylxanthine derivatives, A2A-selective adenosine receptor
`antagonists”. Journal Med. Chem., vol. 43, Issue 3, Jan. 2000, p.
`440-448.
`Schmidt, D. et al., “Fibromatosis of Infancy and Childhood Histol-
`ogy, Ultrastructure and Clinicopathologic Correlation” Zeitschrift
`fur Kinderchirurgie, 1985, vol. 40, No. 1, pp. 40-46.
`Schwartz, M. S. et al., “Type 2 Diabetes Mellitus in Childhood:
`Obesity and Insulin Resistance”. JAOA Review Article, vol. 108, No.
`9, Sep. 2008, p. 518.
`Scientific Discussion: “Eucreas. Scientific discussion”. Online Oct.
`2007, p. 1-27, URL:http://www.emea.europa.eu/humandocs/PDFs/
`EPAIUeucreas/H-807-en6.pdf. see point 2. quality aspects pp. 2-4.
`(EMEA).
`Sedo, A. et al; “Dipeptidyl peptidase IV activity and/or structure
`homologs: Contributing factors in the pathogenesis of rheumatoid
`arthritis?” Arthritis Research & Therapy 2005, vol. 7, pp. 253-269.
`Shanks, N. et al., Are animal models predictive for humans?, PEHM,
`Philosophy, Ethics, and Humanaities in Medicine, 4(2), 2009, 1-20.
`Sharkovska, Y., et al., “DPP-4 Inhibition with Linagliptin Delays the
`Progression of Diabetic Nephropathy in db/db Mice” 48th EASD
`Annual Meeting, Berlin, Abstract 35, Oct. 2012, URL:http://www.
`abstractsonline.com/Plan/ViewAbstract.aspx?sKey:Ob0017b9-
`ge90-4695-b9af-b6870e96a921&cKe}P8eff47ae-db49-4c36-a142-
`848ac068c405&mKey:{2DBFCAF7-1539-42D5-8.
`Shintani, Maki, et al., “Insulin Resistance and Genes” Circulatory
`Sciences (1997) vol. 17, No. 12 pp. 1186-1188.
`Silverman, G. et al., “Handbook of Grignard Reagents” 1996,
`Retrieved online: <http://books.google.com/books?id:82CaxfY-
`uNkC&printsec:frontcover&dq:
`intitle : Handbook+intitle: of+intitle: Grignard+intitle: Reagents&hl:
`en&sa:X&ei:g06GU5SdOKngsATphYCgCg&ved:
`0CDYQ6AEwAA#v:onepage&q&f:false>.
`Singhal, D. et al., “Drug polymorphism and dosage form design: a
`practical perspective” Advanced Drug Delivery Reviews, 2004, vol.
`56, pp. 335-347.
`
`Sortino, M.A. et al ., “Linagliptin: a thorough characterization beyond
`its clinical efficacy” Frontiers in Endocrinology, 2013, vol. 4, Article
`16, pp. 1-9.
`St. John Providence Health Center, “Preventing Obesity in Children
`and Teens” Retrieved from internet on Aug. 22, 2013, http://www.
`stjohnprovidence.org/Health I nfoLib/swarticle.aspx?type:85&id:
`P07863.
`Stahl, PH., “Handbook of Pharmaceutical Salts”. C.G. Wermuth,
`Wiley-VCH, 2002, p. 61.
`Sune Negre, J. M. “New Galenic Contributions to Administration
`Forms”. Continued Training for Hospital Pharmacists 3.2., (Publica-
`tion date unavailable), Retrieved from internet on Feb. 23, 2011,
`http://www.ub.es/1egmh/capitols/sunyenegre.pdf.
`Tarnrn, E, et al., “Double-blind study comparing the immunogenicity
`of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem
`TM) with three investigational, liquid formulations using lower doses
`ofHib-CRM197 conjugate”. Science Direct, Vaccine, Feb. 2005, vol.
`23, No. 14, p. 1715-1719.
`Tanaka, S.. et al; “Suppression of Arthritis by the Inhibitors of
`Dipeptidyl Peptidase IV,” In. J. Immunopharn1ac., vol. 19, No. 1, pp.
`15-24, 1997.
`Targher, G. et al., “Prevalence of Nonalcoholic Fatty Liver Disease
`and Its Association With Cardiovascular Disease Among Type 2
`Diabetic Patients” Diabetes Care, 2007, vol. 30, No. 5, pp. 1212-
`1218.
`Third Party Observation for application No. EP20070728655, May
`13, 2013.
`Thomas, L, et al: “BI 1356, a novel and selective xanthine beased
`DPP-IV inhibitor, exhibits a superior profile when compared to
`sitagliptin and vildagliptin” Diabetologoa, vol. 50, No. Suppl. 1, Sep.
`2007, p. S363.
`Thomas, L., “Chronic treatment with the Dipeptidyl Peptidase-4
`Inhibitor BI 1356[9R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-
`methyl- 1 (4 -methyl-quinazolin-2 -ylmethyl)-3 ,7 -dihydro-purine-2,6 -
`dione]
`Increases Basal Glucagon-Like Peptide-1 and Improves
`Glycemic Control in Diabetic Rodent Models” The Journal of Phar-
`macology and Experimental Therapeutics, Feb. 2009, vol. 328, No. 2,
`pp. 556-563.
`Thomas, Leo et al: “(R)-8-(3 -Amino-piperidin-1-yl)-7-but-2-ynyl-3-
`methyl- 1 -(4 -methyl-quinazolin-2-ylmethyl)-3 ,7 -dihydro-purine-
`2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4
`Inhibitor, Has a Superior Potency and Longer Duration of Action
`Compared with Other Dipeptidyl Peptidase-4 Inhibitors” Journal of
`Pharmacology and Experimental Therapeutics, American Socity for
`Therapeutics, US, vol. 325, No. 1,Apr. 1, 2008, pp. 175-182 abstract
`p. 177, col. 2, paragraph 1 table 1 p. 1B1, col. 2, last paragraph—p.
`182, col. 1.
`Thornber, C.W., “Isosterism and Molecular Modification in Drug
`Design.” Chemical Society Reviews, 1979, pp. 563-580.
`Tounyoubyou, “Symposium-19: Future Perspectives on Incretion
`Therapy in Diabetes” 2008, vol. 51, Suppl. 1, p. S-71, S19-2.
`Tradjenta, Highlights of Prescribing Information (revised Sep.
`2012).
`Tribulova, N. et al. “Chronic Disturbances in NO Production Results
`in Histochemical and Subcellular Alterations of the Rat Heart”
`Physiol. Res., 2000, vol. 49, No. 1, pp. 77-88.
`Tsujihata, et al., “TAK-875, an orally available G protein-Coupled
`receptor 40/Free fatty acid receptor 1 Agonist, Enhances Glucose
`Dependent Insulin Secretion and improves both Postprandial and
`Fasting hyperglycemic in type 2 Diabetic rats”, J. Pharm Exp. 2011,
`vol. 339, No. 1, p. 228-237.
`Tsuprykov, O. et al., Linagliptin is as Efficacious as Telmisartan in
`Preventing Renal Disease Progression in Rats with 5/6 Nephrectomy,
`73rd Annual Meeting Science Session, ADA, Chicago, Jun. 2013
`URl:http://www.abstractsonline.com/Plan/ViewAbstract.
`aspx? sKey:e6 8ac573 -fe45 -4c2f-9485 -6278854fc18b&cKey:
`3c387569-84de-4f8c-b8.
`U.S. Appl. No. 12/724,653, filed Mar. 16, 2010—Xanthine Deriva-
`tives, the Preparation Thereof and Their Use as Pharmaceutical Com-
`positions. Inventor: Frank Himmelsbach, et al.
`U.S. Appl. No. 12/767,855, filed Apr. 27, 2010—Xanthine Deriva-
`tives, the Preparation Thereof and Their use as Pharmaceutical Com-
`positions. Inventor: Frank Himmelsbach, et al.
`
`MYLAN Ex. 1001, Page 6
`
`MYLAN Ex. 1001, Page 6
`
`

`
`US 9,173,859 B2
`Page 7
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Uhlig-Laske, B. et al., “Linagliptin, a Potent and Selective DPP-4
`Inhibitior, is Safe and Efficacious in Patients with Inadequately Con-
`trolled Type 2 Diabetes Despite Metformin Therapy”. 535-P Clinical
`Therapeutics/New Technology—Pharmacologic Treatment of Dia-
`betes or Its Complications, Posters, vol. 58, Jun. 5, 2009, p. A143.
`United Healthcare, “Diabetes.” Retrieved from internet on Aug. 22,
`2013,
`http://www.uhc.com/source4women/health_topics/
`diabetesirelatedinformation/
`dOf0417b073bf11OVgnVCM1000002f10b10a _. htrn.
`Villhauer,
`E.B.,
`“1-[[3 -Hydroxy-1-adamantyl)arnino]acetyl]-1-
`cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable
`Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Proper-
`ties” Journal Med. Chem, 2003, 46, p. 2774-2789.
`Villhauer, E.B.,
`et
`al.,
`“1-{2-{5-Cyanopyridin-2-yl)amino}-
`ethylamino}acetyl-1-1(S)-pyrrolidine-carbonitrile: A Potent, Selec-
`tive, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with
`Antihyperglycemic Properties”. Journal ofMedical Chemistry, 2002,
`vol. 45, No. 12, p. 2362-2365.
`Wang Y et
`al:
`“BI-1356. Dipeptidyl-peptidase IV inhibitor,
`antidiabetic agent” Drugs of the Future, Prous Science, ES,vol. 33,
`No.6, Jun. 1, 2008, pp. 473-477.
`Wertheimer, et al., “Drug Delivery Systems improve pharmaceutical
`profile and faciliate medication adherence”, Adv. Therapy 22: p.
`559-577 (2005).
`“Dipeptidyl Peptidase-IV Inhibitors:
`Jr.,
`White,
`John R.
`Phamacological Profile and Clinical Use”. Clinical Diabetes, Apr.
`2008, vol. 26, No. 2, pp. 53-57.
`Wikipedia, Annulation. Jun. 23, 2008, http://en.wikipedia.org/wiki/
`Annelation.
`Williams-Herman, D. et al., “Efficacy and safety of initial combina-
`tion therapy with sitagliptin and metformin in patients with type 2
`diabetes: a 54-week stu